Vertex Pharmaceuticals Incorporated (FRA:VX1)

Market Cap	102.83B -14.8%
Revenue (ttm)	10.22B +8.9%
Net Income	3.37B
EPS	13.05
Shares Out	n/a
PE Ratio	30.54
Forward PE	24.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36
Average Volume	61
Open	398.50
Previous Close	398.95
Day's Range	397.65 - 404.85
52-Week Range	313.75 - 475.00
Beta	n/a
RSI	53.46
Earnings Date	Feb 12, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,400
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VX1

Financial Performance

Financial numbers in USD